Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Krystal Biotech ( (KRYS) ) just unveiled an announcement.
Krystal Biotech announced promising early clinical results for its genetic medicine programs, KB408 and KB407, aimed at treating rare respiratory diseases. The data indicates successful gene delivery and expression in the lungs, with both treatments showing good safety and tolerability profiles. These findings support the potential of Krystal’s platform to provide effective, non-invasive therapies for diseases like alpha-1 antitrypsin deficiency and cystic fibrosis, marking a significant advancement in their pipeline and potentially enhancing their market position.
More about Krystal Biotech
Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on developing genetic medicines to address diseases with high unmet medical needs. The company’s offerings include VYJUVEK®, the first-ever redosable gene therapy approved by the FDA for treating dystrophic epidermolysis bullosa. Their pipeline spans various therapeutic areas such as respiratory, oncology, dermatology, ophthalmology, and aesthetics.
YTD Price Performance: 50.83%
Average Trading Volume: 231,811
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $5.38B
For a thorough assessment of KRYS stock, go to TipRanks’ Stock Analysis page.
